Okogen, Inc.
Small-molecule therapeutic drug for acute infectious conjunctivitis in Phase 2B clinical trials
- Sector
- Biotech
- Headquarters
- Plano, TX
- Founded
- 2016
- Latest Form D
- $2.5M, Dec 2024
- Total capital
- $8.9M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $8.9M
- 3 Form D · last Dec 2024
- 22 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 10 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$2.5M
- Private capital raisedForm D · SEC · 2nd filing$213K
- Private capital raisedForm D · SEC · 1st filing$6.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Bradford J. ConlanDirector, PromoterNamed in SEC Form D filings
- Brian StremExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Chris SmithDirectorNamed in SEC Form D filings
- Eric DanielsExecutive Officer, PromoterNamed in SEC Form D filings
- Josh MoriartyExecutive Officer, PromoterNamed in SEC Form D filings
- Joshua MoriartyExecutive Officer, DirectorNamed in SEC Form D filings
Show all 8 people
- Leighton ReidDirectorNamed in SEC Form D filings
- Quinton J. OswaldDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 10- PendingRibonucleases For Treating Viral InfectionsUSPTOApplication 17906631
- PendingPharmaceutical Compositions Comprising RanpirnaseUSPTOApplication 18547164
- PendingTreatment Of Viral ConjunctivitisUSPTOApplication 17996577
Show all 10 patent records
- Ribonucleases For Treating Viral InfectionsNov 6, 2025 · Application 17906631Pending
- Pharmaceutical Compositions Comprising RanpirnaseApr 18, 2024 · Application 18547164Pending
- Treatment Of Viral ConjunctivitisJul 13, 2023 · Application 17996577Pending
- Viral Conjunctivitis Treatment Using Ranpirnase And/or AmphinaseAug 25, 2022 · Application 17650220Pending
- Methods And Pharmaceuticals For Treatment Of Viral Infections Of The EyeJul 18, 2019 · Application 16368330Pending
- Viral Conjunctivitis Treatment Using RanpirnaseSep 14, 2017 · Application 15604523Pending
- Treatment Of Viral ConjunctivitisApplication PCTUS2021028693Pending
- Methods Of Treating Ocular MelanomaApplication PCTUS2019032715Pending
- Methods Of Treating Ocular MelanomaApplication 62673740Pending
- Treatment Of Viral ConjunctivitisApplication 63014380Pending
Related companies, and why
- Lattice Biologics Ltd.Similar federal contract value in Biotech · null in contracts
- EnGeneIC LtdSimilar federal contract value in Biotech · null in contracts
- ALPINE IMMUNE SCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- Protagenic Therapeutics, Inc.\newSimilar federal contract value in Biotech · null in contracts
- GREENLAB, INC.Similar federal contract value in Biotech · null in contracts
- Advenchen Laboratories, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .